Gregory M. Glenn's most recent trade in Novavax, Inc. was a trade of 6,298 Restricted Stock Units done . Disclosure was reported to the exchange on March 6, 2023.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Mar 2023 | 6,298 | 12,596 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.52 per share. | 06 Mar 2023 | 6,298 | 20,771 (0%) | 0% | 6.5 | 41,063 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Purchase of securities on an exchange or from another person at price $ 7.48 per share. | 06 Mar 2023 | 3,000 | 11,473 (0%) | 0% | 7.5 | 22,454 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.52 per share. | 06 Mar 2023 | 2,432 | 18,339 (0%) | 0% | 6.5 | 15,857 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Purchase of securities on an exchange or from another person at price $ 7.04 per share. | 06 Mar 2023 | 2,000 | 13,473 (0%) | 0% | 7.0 | 14,088 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Purchase of securities on an exchange or from another person at price $ 6.50 per share. | 06 Mar 2023 | 1,000 | 14,473 (0%) | 0% | 6.5 | 6,500 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 28,341 | 28,341 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Mar 2022 | 18,894 | 18,894 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2021 | 3,100 | 7,161 (0%) | 0% | - | Common Stock | |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2021 | 3,100 | 6,200 | - | - | Restricted Stock Units | |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 168.43 per share. | 14 Dec 2021 | 1,498 | 5,663 (0%) | 0% | 168.4 | 252,308 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 27.60 per share. | 14 Dec 2021 | 1,024 | 6,687 (0%) | 0% | 27.6 | 28,262 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2021 | 1,024 | 0 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Dec 2021 | 662 | 7,944 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.00 per share. | 14 Dec 2021 | 662 | 7,349 (0%) | 0% | 46 | 30,452 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 171.47 per share. | 14 Dec 2021 | 254 | 6,765 (0%) | 0% | 171.5 | 43,553 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 172.38 per share. | 14 Dec 2021 | 248 | 6,517 (0%) | 0% | 172.4 | 42,750 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 176.83 per share. | 14 Dec 2021 | 223 | 5,999 (0%) | 0% | 176.8 | 39,432 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 170.46 per share. | 14 Dec 2021 | 213 | 7,019 (0%) | 0% | 170.5 | 36,309 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 179.58 per share. | 14 Dec 2021 | 206 | 5,690 (0%) | 0% | 179.6 | 36,993 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 174.65 per share. | 14 Dec 2021 | 137 | 6,289 (0%) | 0% | 174.6 | 23,927 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 168.82 per share. | 14 Dec 2021 | 117 | 7,232 (0%) | 0% | 168.8 | 19,752 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 178.99 per share. | 14 Dec 2021 | 103 | 5,896 (0%) | 0% | 179.0 | 18,436 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 173.30 per share. | 14 Dec 2021 | 91 | 6,426 (0%) | 0% | 173.3 | 15,770 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 175.90 per share. | 14 Dec 2021 | 67 | 6,222 (0%) | 0% | 175.9 | 11,785 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 180.63 per share. | 14 Dec 2021 | 27 | 5,663 (0%) | 0% | 180.6 | 4,877 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Dec 2021 | 8,250 | 82,500 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.08 per share. | 07 Dec 2021 | 8,250 | 12,311 (0%) | 0% | 19.1 | 157,410 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 175.13 per share. | 07 Dec 2021 | 900 | 7,314 (0%) | 0% | 175.1 | 157,619 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 182.30 per share. | 07 Dec 2021 | 853 | 4,161 (0%) | 0% | 182.3 | 155,498 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 176.20 per share. | 07 Dec 2021 | 800 | 6,514 (0%) | 0% | 176.2 | 140,956 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 180.29 per share. | 07 Dec 2021 | 500 | 5,014 (0%) | 0% | 180.3 | 90,147 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 179.36 per share. | 07 Dec 2021 | 500 | 5,514 (0%) | 0% | 179.4 | 89,680 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 178.21 per share. | 07 Dec 2021 | 500 | 6,014 (0%) | 0% | 178.2 | 89,104 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 168.77 per share. | 07 Dec 2021 | 400 | 8,614 (0%) | 0% | 168.8 | 67,508 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 153.53 per share. | 07 Dec 2021 | 397 | 11,614 (0%) | 0% | 153.5 | 60,951 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 167.06 per share. | 07 Dec 2021 | 300 | 9,014 (0%) | 0% | 167.1 | 50,118 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 165.80 per share. | 07 Dec 2021 | 300 | 9,314 (0%) | 0% | 165.8 | 49,739 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 164.77 per share. | 07 Dec 2021 | 300 | 9,614 (0%) | 0% | 164.8 | 49,430 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 161.63 per share. | 07 Dec 2021 | 300 | 10,114 (0%) | 0% | 161.6 | 48,490 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 160.52 per share. | 07 Dec 2021 | 300 | 10,414 (0%) | 0% | 160.5 | 48,157 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 158.42 per share. | 07 Dec 2021 | 300 | 10,714 (0%) | 0% | 158.4 | 47,527 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 156.24 per share. | 07 Dec 2021 | 300 | 11,214 (0%) | 0% | 156.2 | 46,873 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 173.14 per share. | 07 Dec 2021 | 200 | 8,214 (0%) | 0% | 173.1 | 34,627 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 171.30 per share. | 07 Dec 2021 | 200 | 8,414 (0%) | 0% | 171.3 | 34,260 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 162.82 per share. | 07 Dec 2021 | 200 | 9,914 (0%) | 0% | 162.8 | 32,565 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 157.02 per share. | 07 Dec 2021 | 200 | 11,014 (0%) | 0% | 157.0 | 31,404 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 150.30 per share. | 07 Dec 2021 | 200 | 12,111 (0%) | 0% | 150.3 | 30,059 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 182.96 per share. | 07 Dec 2021 | 100 | 4,061 (0%) | 0% | 183.0 | 18,296 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 154.38 per share. | 07 Dec 2021 | 100 | 11,514 (0%) | 0% | 154.4 | 15,438 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 151.85 per share. | 07 Dec 2021 | 100 | 12,011 (0%) | 0% | 151.9 | 15,185 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.08 per share. | 30 Nov 2021 | 8,250 | 13,003 (0%) | 0% | 19.1 | 157,410 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Nov 2021 | 8,250 | 90,750 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 208.78 per share. | 30 Nov 2021 | 1,450 | 5,591 (0%) | 0% | 208.8 | 302,727 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 209.81 per share. | 30 Nov 2021 | 879 | 4,712 (0%) | 0% | 209.8 | 184,419 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 198.17 per share. | 30 Nov 2021 | 836 | 10,746 (0%) | 0% | 198.2 | 165,670 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 200.40 per share. | 30 Nov 2021 | 717 | 9,351 (0%) | 0% | 200.4 | 143,690 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 202.37 per share. | 30 Nov 2021 | 715 | 8,298 (0%) | 0% | 202.4 | 144,692 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 199.25 per share. | 30 Nov 2021 | 678 | 10,068 (0%) | 0% | 199.2 | 135,091 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 210.57 per share. | 30 Nov 2021 | 551 | 4,161 (0%) | 0% | 210.6 | 116,026 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 195.87 per share. | 30 Nov 2021 | 518 | 11,938 (0%) | 0% | 195.9 | 101,460 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 203.79 per share. | 30 Nov 2021 | 465 | 7,833 (0%) | 0% | 203.8 | 94,764 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 206.06 per share. | 30 Nov 2021 | 439 | 7,394 (0%) | 0% | 206.1 | 90,462 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 197.31 per share. | 30 Nov 2021 | 356 | 11,582 (0%) | 0% | 197.3 | 70,242 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 207.19 per share. | 30 Nov 2021 | 353 | 7,041 (0%) | 0% | 207.2 | 73,139 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 201.23 per share. | 30 Nov 2021 | 338 | 9,013 (0%) | 0% | 201.2 | 68,015 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 192.58 per share. | 30 Nov 2021 | 222 | 12,656 (0%) | 0% | 192.6 | 42,752 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 194.62 per share. | 30 Nov 2021 | 200 | 12,456 (0%) | 0% | 194.6 | 38,923 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 189.98 per share. | 30 Nov 2021 | 121 | 12,882 (0%) | 0% | 190.0 | 22,987 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 211.75 per share. | 30 Nov 2021 | 100 | 4,061 (0%) | 0% | 211.8 | 21,175 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 191.25 per share. | 30 Nov 2021 | 4 | 12,878 (0%) | 0% | 191.3 | 765 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2021 | 2,083 | 45,834 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.95 per share. | 26 Nov 2021 | 2,083 | 6,144 (0%) | 0% | 6.0 | 12,394 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Nov 2021 | 1,377 | 30,296 | - | - | Stock Appreciation Right | |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 5.95 per share. | 26 Nov 2021 | 1,377 | 5,438 (0%) | 0% | 5.9 | 8,193 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Payment of exercise price or tax liability using portion of securities received from the company at price $ 217.97 per share. | 26 Nov 2021 | 647 | 4,753 (0%) | 0% | 218.0 | 141,027 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 218.25 per share. | 26 Nov 2021 | 626 | 4,742 (0%) | 0% | 218.3 | 136,627 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 219.25 per share. | 26 Nov 2021 | 412 | 4,330 (0%) | 0% | 219.3 | 90,333 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 217.36 per share. | 26 Nov 2021 | 331 | 5,368 (0%) | 0% | 217.4 | 71,946 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 216.19 per share. | 26 Nov 2021 | 260 | 5,699 (0%) | 0% | 216.2 | 56,209 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 215.01 per share. | 26 Nov 2021 | 185 | 5,959 (0%) | 0% | 215.0 | 39,776 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 220.22 per share. | 26 Nov 2021 | 155 | 4,175 (0%) | 0% | 220.2 | 34,134 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 221.25 per share. | 26 Nov 2021 | 114 | 4,061 (0%) | 0% | 221.2 | 25,222 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale or transfer of securities back to the company at price $ 217.97 per share. | 26 Nov 2021 | 38 | 5,400 (0%) | 0% | 218.0 | 8,283 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Nov 2021 | 8,250 | 99,000 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.08 per share. | 23 Nov 2021 | 8,250 | 12,311 (0%) | 0% | 19.1 | 157,410 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 200.55 per share. | 23 Nov 2021 | 1,600 | 5,853 (0%) | 0% | 200.6 | 320,887 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 197.44 per share. | 23 Nov 2021 | 1,400 | 10,111 (0%) | 0% | 197.4 | 276,419 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 199.51 per share. | 23 Nov 2021 | 1,387 | 7,453 (0%) | 0% | 199.5 | 276,720 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 198.47 per share. | 23 Nov 2021 | 1,271 | 8,840 (0%) | 0% | 198.5 | 252,252 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 202.65 per share. | 23 Nov 2021 | 870 | 4,261 (0%) | 0% | 202.6 | 176,302 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 196.43 per share. | 23 Nov 2021 | 800 | 11,511 (0%) | 0% | 196.4 | 157,143 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 201.48 per share. | 23 Nov 2021 | 722 | 5,131 (0%) | 0% | 201.5 | 145,468 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 203.62 per share. | 23 Nov 2021 | 200 | 4,061 (0%) | 0% | 203.6 | 40,723 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 19.08 per share. | 15 Nov 2021 | 8,250 | 12,311 (0%) | 0% | 19.1 | 157,410 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Nov 2021 | 8,250 | 107,250 | - | - | Stock Option (Right to Buy) | |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 170.26 per share. | 15 Nov 2021 | 4,352 | 4,661 (0%) | 0% | 170.3 | 740,977 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 167.95 per share. | 15 Nov 2021 | 1,472 | 10,339 (0%) | 0% | 168.0 | 247,225 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 168.91 per share. | 15 Nov 2021 | 1,326 | 9,013 (0%) | 0% | 168.9 | 223,969 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Sale of securities on an exchange or to another person at price $ 172.02 per share. | 15 Nov 2021 | 1,183 | 4,061 (0%) | 0% | 172.0 | 203,496 | Common Stock |
| Novavax, Inc. | Gregory M. Glenn | President, R&D | Exercise or conversion of derivative security received from the company (such as an option) at price $ 46.00 per share. | 15 Nov 2021 | 662 | 5,244 (0%) | 0% | 46 | 30,452 | Common Stock |